Your Immune System Is Aging Faster Than You Are, and the Thymus Is the First Domino to Fall

#1

Three researchers at the Polish Academy of Sciences have pulled together the current picture of how the immune system decays with age, spanning the organs that build immune cells (bone marrow and thymus) and the ones that deploy them (spleen and lymph nodes), plus the individual cell types. The core story is that the thymus shrinks by roughly three percent per year from about age one, the factory that makes fresh naive T cells slowly closes, senescent cells pile up and leak inflammatory signals, and the result is worse infection defense, weaker vaccine responses, and higher cancer and autoimmune risk. The more useful half of the paper is the translational section, which catalogs what actually moves these markers in humans: caloric restriction, exercise, stress regulation, and specially formulated vaccines for older adults.

The immune system does not age all at once, and this review’s central contribution is to show how staggered and organ specific the decline really is. The clearest single number in the whole field sits in the thymus, the small organ behind the breastbone where T cells learn to tell self from invader. It reaches peak size around your first birthday and then shrinks at about three percent per year into middle age. As it involutes, the supply of new naive T cells falls, the diversity of the T cell receptor repertoire narrows, and the body increasingly relies on an aging stock of memory cells that it already has rather than fresh cells able to recognize new threats.

Underneath that, the review lays out the machinery. Aging hematopoietic stem cells in the bone marrow drift toward making myeloid cells at the expense of lymphoid cells. Mesenchymal stromal cells turn senescent, accumulate reactive oxygen species, express p16 and p21, and start secreting the inflammatory cocktail known as the senescence associated secretory phenotype. That secretory phenotype, rich in interleukin 6, is the molecular engine of what the field calls inflammaging, the chronic low grade inflammation that tracks with mortality in large cohorts such as Framingham and Rancho Bernardo.

The big idea is not any one finding but the synthesis: immune aging is a network failure in which structural collapse of lymphoid organs, functional exhaustion of individual cells, and a rising tide of senescent cells reinforce each other. The reason this matters beyond the lab is that older immune systems fail at exactly the tasks we ask of them in old age. They mount weaker responses to vaccines, clear infections more slowly, and police cancerous and senescent cells less effectively.

What lifts this review above a textbook chapter is that it does not stop at describing damage. It reviews human interventions that measurably shift the trajectory. Two years of moderate caloric restriction preserved thymic volume and lowered inflammatory markers. Structured exercise cut senescence markers inside circulating T cells. Reformulated vaccines restored strong protection in the over seventies. None of these has yet been shown to extend human lifespan, and the authors are careful to say so, but the direction of travel is that immune aging is partially modifiable rather than fixed.

Actionable insights (with effect sizes)

The single strongest quantified intervention in the paper is not a supplement, it is a vaccine choice. The adjuvanted recombinant zoster vaccine (Shingrix) showed 97.2 percent efficacy against shingles in the ZOE-50 trial and 89.8 percent in adults over seventy in ZOE-70. In plain terms, that is roughly a ten to one reduction in risk, meaning about nine in ten cases that would have happened are prevented. High dose influenza vaccine, with four times the standard antigen, meaningfully cut influenza hospitalization in the over sixty fives. If you are over sixty five, choosing the age formulated versions is the highest yield immune move available.

For lifestyle, the two year CALERIE-2 trial of 25 percent caloric restriction preserved or increased thymic volume, raised recent thymic emigrants, lowered C-reactive protein and TNF-alpha, and slowed the DunedinPACE epigenetic aging clock. Structured aerobic exercise lowered p16, p21, cGAS, and TNF-alpha inside T cells and raised naive T cell proportions and NK cytotoxicity. The review reports these as directional improvements and does not publish standardized effect sizes for them, so treat the magnitude as real but modest rather than dramatic.

Context and source

  • Open Access Paper: What Do We Know About Immune System Aging from Human and Animal Studies?
  • Authors and institution: Marta Cakala-Jakimowicz, Anna Domaszewska-Szostek, and Monika Puzianowska-Kuznicka, Mossakowski Medical Research Institute, Polish Academy of Sciences, and the Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Journal: International Journal of Molecular Sciences (IJMS), published by MDPI, Basel, Switzerland. published 5 July 2026.
  • Impact evaluation: The impact score of this journal is 5.6 (2025 Journal Citation Report Impact Factor; CiteScore 10.0), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low to Medium impact journal. Two caveats sharpen that read. First, IJMS is a very large, high volume MDPI journal, and its impact factor is diluted across an enormous article count rather than concentrated in a selective flagship. Second, for a narrative review the journal metric is a weak proxy for reliability anyway, since a review is only as good as the primary trials it cites. Judge this paper on the quality of the human trials it references, not on the masthead.

Related Reading:

1 Like
#2

Effect sizes

The one place with a clean, large effect size is vaccination. Vaccine efficacy is itself a relative risk reduction. The adjuvanted zoster vaccine reported 97.2 percent efficacy (ZOE-50) and 89.8 percent efficacy in the over seventies (ZOE-70). Read as relative risk, an efficacy of 89.8 percent means the relative risk of shingles in the vaccinated group is about 0.10 versus placebo, so roughly a ninety percent reduction in cases. This is a large, unambiguous effect, and it is the strongest quantified result in the paper. For a non statistician: if a hundred unvaccinated older adults would get shingles, only about ten vaccinated ones do.

Caloric restriction (CALERIE-2, 25 percent restriction for two years) is described qualitatively. The review states that the intervention group preserved or increased thymic volume, had higher recent thymic emigrants, and had lower C-reactive protein and TNF-alpha, plus a measurable slowing of biological aging on the DunedinPACE clock. The review does not print the raw means, standard deviations, or a Cohen’s d, so a standardized effect size cannot be computed from the text. Context from the underlying CALERIE literature is that the DunedinPACE slowing was statistically significant but small in absolute terms (a low single digit percentage slowing of the pace of aging). Translation for the non statistician: the direction is good and it is real, but it is a nudge, not a transformation, and you should not expect a dramatic personal effect.

Exercise and stress regulation are likewise reported as directional. Exercise lowered senescence markers (p16, p21, cGAS, TNF-alpha) in T cells and raised naive T cell fraction and NK cytotoxicity. Habitual cognitive reappraisal in high stress individuals was associated with lower late differentiated CD8 T cells, lower NK late differentiation, and lower circulating IL-6. No effect sizes are provided for any of these, so treat them as qualitative associations rather than quantified benefits.

The senolytic data are early and, importantly, mostly null on function. The first dasatinib plus quercetin trial (nine patients, single arm, open label) showed reduced senescent cell burden and lower circulating SASP factors within days. The follow up randomized feasibility trial in idiopathic pulmonary fibrosis (twelve participants) found no statistically significant change in functional endpoints. So the biomarker moved, the outcome did not, in a tiny sample.

Bottom line for effect sizes: one large, well quantified effect (age formulated vaccines, roughly ninety percent relative risk reduction for zoster), and a set of directionally favorable but unquantified or small lifestyle and pharmacological signals. [Confidence: High for the vaccine figures, which are directly quoted trial results. Confidence: Medium to Low for the magnitude of lifestyle effects, because the review reports them without effect sizes.]

1 Like